Home › Leukemia › Texas › Houston
Leukemia clinical trials in Houston, TX
28 studies for Leukemia are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RecruitingPhase 3
- Quetzal Site 6, Houston
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
RecruitingPhase 1
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RecruitingPhase 2
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecruitingPhase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RecruitingPhase 2
- MD Anderson Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
RecruitingPhase 3
- Research Site, Houston
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
RecruitingPhase 1
- Texas Children's Hospital, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RecruitingPhase 1/2
- MD Anderson Cancer Center, Houston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
- University of Texas, Houston
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
RecruitingPhase 1/2
- Research Site, Houston
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RecruitingPhase 2
- Baylor Texas Children's Hospital, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RecruitingPhase 2
- University of Texas MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
RecruitingPhase 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of Revumenib and Mezigdomide in People With Leukemia
RecruitingPhase 1/2
- MD Anderson Cancer Center (Data Collection Only), Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
RecruitingPhase 1/2
- Dren Investigational Site, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
- Texas Children's Hospital, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
RecruitingObservational study
- M D Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RecruitingObservational study
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- MD Anderson Cancer Center, Houston
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Houston
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RecruitingPhase 1
- The University of Texas M.D. Anderson Cancer Center, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
About Leukemia
Leukemia is cancer of the white blood cells. There are two types of Leukemias, acute and chronic. Learn about the differences and treatments available.
More about Leukemia on MedlinePlus
Leukemia trials in other cities
- Boston, MA25 studies
- New York City, NY19 studies
- Los Angeles, CA16 studies
- Chicago, IL16 studies
- Durham, NC13 studies
- Baldwin Park, CA12 studies
- Columbus, OH12 studies
- Nashville, TN12 studies
- Philadelphia, PA12 studies
- Seattle, WA11 studies
- Milwaukee, WI11 studies
- Birmingham, AL10 studies
Other studies in Houston
- Non-Small Cell Lung Cancer145 studies
- Breast Cancer126 studies
- Cancer (all types)122 studies
- Metastatic Cancer104 studies
- Colorectal Cancer103 studies
- Ovarian Cancer90 studies
- Acute Myeloid Leukemia86 studies
- Lung Cancer78 studies
- Prostate Cancer76 studies
- Endometrial Cancer69 studies
- Pancreatic Cancer62 studies
- Melanoma59 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.